Biomedical Research Institute, Ninewells Hospital and Medical School, University of Dundee, Angus, Dundee, United Kingdom DD1 9SY.
J Clin Endocrinol Metab. 2010 Apr;95(4):1830-7. doi: 10.1210/jc.2009-1201. Epub 2010 Mar 3.
Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity.
The objective of the study was to determine whether rs2016520 or other single-nucleotide polymorphism in the PPARD locus influenced the risk of developing various characteristics of metabolic disease.
Haplotype tagging analysis across PPARD was performed in 11,074 individuals from the Welcome Trust U.K. Type 2 Diabetes Case Control Collection.
In subjects with and without type 2 diabetes, rs2016520 was associated with body mass index, high-density lipoprotein cholesterol, leptin, and TNFalpha and was dependent on gender.
The current results suggest differential effects of PPARdelta in males and females.
先前的研究已经确定了编码过氧化物酶体增殖物激活受体-δ（PPARD）的基因中的一个单核苷酸多态性（rs2016520）与某些但不是所有研究中代谢疾病的变化有关，这表明 PPARD 激动剂可能对治疗代谢紊乱，包括血脂异常、2 型糖尿病和肥胖症具有治疗益处。
本研究的目的是确定 rs2016520 或 PPARD 基因座中的其他单核苷酸多态性是否会影响发生各种代谢疾病特征的风险。
在来自英国信托基金 2 型糖尿病病例对照收集的 11074 名个体中进行了 PPARD 的单倍型标记分析。
在患有和不患有 2 型糖尿病的个体中，rs2016520 与体重指数、高密度脂蛋白胆固醇、瘦素和 TNFalpha 相关，且依赖于性别。
目前的结果表明 PPARdelta 在男性和女性中的作用存在差异。
